Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LINC00355 LNA ASOs
- Development stage
- Preclinical
- Lead developer
- Washington University in St. Louis
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
LINC00355 LNA ASOs are locked nucleic acid-based antisense oligonucleotides (GapmeRs) designed to target and reduce the expression of the long non-coding RNA LINC00355. Developed by researchers at Washington University in St. Louis, these ASOs are being investigated for the treatment of late-stage relapse (LSR) breast cancer, particularly ER+/HER2- breast cancer. LINC00355 is highly upregulated in late-stage relapse breast cancer and binds to the MENIN protein, which in turn decreases CDKN1B (p27Kip) expression to promote cellular proliferation and drive resistance to CDK4/6 inhibitors. By silencing LINC00355, these LNA ASOs disrupt the LINC00355-MENIN interaction, restore CDKN1B expression, and reduce cancer cell proliferation, especially when used in combination with CDK4/6 inhibitors like palbociclib or ribociclib.
- Other names
- LINC00355 LNA GapmeRsLINC-00355 LNA GapmeRsLINC 00355 LNA GapmeRsLINC00355 antisense oligonucleotidesLINC-00355 antisense oligonucleotidesLINC 00355 antisense oligonucleotides
Beyond the preview
Go deeper on LINC00355 LNA ASOs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LINC00355 LNA ASOs.